DataWatch Health Care Innovation In An Era Of Cost Containment
With the health bill for the United States rising from $393 billion in 1984 to an estimated three times that amount in a decade, every medical care expenditure of any consequence is coming under closer scrutiny. 1 Research and development (R and D) activities, though no exception, represent the lifeblood of future innovation which patients have come to expect. Thus, an important question to ask in relationship to R and D expenditures is: what is the effect of the growing societal concern over high medical costs and the delivery system's movement to price competition on innovation?
This DataWatch examines some of the trends in four categories of R and D spending: pharmaceuticals, medical devices, biotechnology, and federal support for biomedical research. There is no central repository for data on R and D spending. As a consequence, it is impossible to provide a total picture of spending for innovation. Nevertheless, this DataWatch provides a glimpse of the rate and types of R and D spending and a recognition that the drive to constrain health care costs will affect innovation. Spending for health R and D has thus far remained robust, but some shifts are occurring which show that growth in private investment, compared with federal expenditures, is greater in percentage terms.
Pharmaceuticals
In the field of pharmaceuticals, R and D is carried out in large part by industry. Seventy percent of U.S. R and D in pharmaceuticals is performed by industry; colleges and universities carry out 10 percent; and the government and other sources make up the remaining 20 percent.
2 Exhibit 1 charts the increasing level of funding committed by industry to research and tracks the industry's domestic and foreign investment in innovation. Another measure of industry research commitment is the ratio of R and D to sales. The pharmaceutical industry has allocated over 10 percent of its expenditures each year for drug research and development, a ratio that is second only to the information processing and semiconductor industries. The 1983 figure is estimated at 14.4 percent. ciples may influence some companies' decisions on how and where they spend their research funds. The high costs of developing a new drug in the U.S. has resulted in an increasing number of U.S. firms conducting their research overseas. Since 1967, this research conducted outside the U.S. has more than doubled, reaching 18.4 percent of U.S. companies' R and D funds in 1983. 4 The costs of developing a new drug in the U.S. have risen from a range of $3-16 million before 1962 to $26-57 million after 1962, due in large part to the lengthy patent process that new drugs must pass through before reaching the market. 5 One study estimates that the cost of developing a new drug in the U.S. in 1983 averaged about $91 million, while others predict that by the year 2000 the costs could approach $150 million to develop a major new pharmaceutical. 6 In addition, a recent study by the Office of Technology Assessment (OTA) found that "recent trends indicate that the rate of innovation return to pharma-DATAWATCH 107 ceutical companies throughout the world has declined. In short, fewer new drug introductions are emanating from larger research commitments by the public and industry." 7 Exhibit 2 charts the decreasing number of new drugs introduced each year worldwide.
In an effort to improve the pay-off of the pharmaceutical companies' major investment and also provide new incentives for the development of generics, Congress enacted the Competition and Patent Term Restoration Act of 1984. Under the new law, a pharmaceutical patent may be extended up to five years beyond the prescribed seventeen by matching year for year the amount of time spent waiting for Food and Drug Administration (FDA) approval. The effective patent life left after approval, however, must not exceed fourteen years. The bill also allows drug companies to use abbreviated new drug applications for generics of drugs approved by the FDA after 1962.
The bulk of industry research funds are spent on product innovation. In 1982, nearly 80 percent of the company-financed R and D expenditures in the U.S. were for research which advanced the scientific knowledge and development of new drug products, while 20 percent was spent on improving existing drugs. 8 Innovation in drug research tends to parallel the major health prob- My guess is that this is a conservative estimate. The reasons for this are twofold, the first being the mobilization of the scientific power of the developed world to work on the great diseases of the developing world which heretofore have been almost totally ignored, and which include malaria, schistosomiasis, etc. Far more important, however, is the new found power of biotechnology in the area of vaccine development and production." 9 The Department of Health and Human Services (HHS) has slated ten vaccines for accelerated development. These include vaccines for meningitis; gonorrhea; croup/ pneumonia in infants and children; an improved whooping cough vaccine; influenza; diarrhea caused by typhoid, shigellosis, rotavirus, and cholera; hepatitis type A and a second generation type B; chickenpox; genital herpes; and malaria. 
Medical Devices
The development of medical devices has also burgeoned. The medical device industry -3,500 companies strong in 1984 -is composed of many small enterprises in contrast to the limited number of giants which dominate pharmaceuticals. 10 A device includes "any instrument, apparatus, or similar article that is intended to prevent, diagnose, mitigate, or treat disease, or to affect the structure or function of the body."
11 Industry sales grew from $1 billion in 1958 to $17 billion in 1983, a sixfold increase, even after adjustment is made for inflation.
12 Employment increased from 65,000 workers in 1958 to 200,000 last year. 13 The direction of innovation in the medical device industry appears to be changing in the face of new economic incentives deriving from Medicare's prospective payment system. Before enactment of this new payment mode, which encourages hospitals through economic incentives to reduce their expenditures, the market for devices was expansionary. It encouraged the development of technology that improved medical information, diagnostic or therapeutic outcomes, or patient and provider convenience. Cost was a secondary consideration because reimbursement systems were structured to pay a hospital's reasonable costs, whatever they might be.
14 Under Medicare's new payment approach, hospitals are paid fixed rates, as measured by diagnosis-related groups (DRGs). Thus, medical device R and D is shifting direction in an effort to bolster the capacity of hospitals to take advantage of DRG categories that prove the most profitable by reducing the length of a patient stay, controling use of ancillary services, and otherwise improving productivity. One concern of the Health Industry Manufacturers Association, according to a former vice-president, Wayne Roe, is that by placing a greater emphasis on the development of cost-reducing technologies, other innovations which could contribute to long-term cost-effectiveness may be neglected under Medicare's new incentives. 15 In examining the data for medical technology research and development, several difficulties emerge. First, basic research and some applied research is difficult to apply to specific devices or even classes of devices. Second, technology data is not currently aggregated or classified in a cohesive manner. The following exhibits from OTA, however, give a glimpse of the trends in medical device innovation. The bulk of R and D for medical devices, like pharmaceuticals, is concentrated in industry, since the research can be targeted to a commercial device. In 1980, the federal government supported less than 3 percent of the research conducted by medical device firms. 16 Exhibit 4 details the level of industry R and D spending for medical devices in five product categories.
Overall, the company-sponsored R and D for medical devices in 1980 equaled 3 percent of the value of the companies' shipments. 17 Within the medical device industry, it appears that small firms with under 500 employees were over twice as innovative a large firms, according to a study of 1982 innovations by the OTA. It seems that small firms are less inhibited by the organizational structures of large firms which can delay innovation. (See Exhibit 5.) Another method of assessing technological innovation is to track patent activity. Exhibit 6 shows data for the number of patents granted in the medical devices industry by date of patent grant and date of patent application. The latter is the more accurate barometer of technological activity. Of the 100,000 patent applications submitted each year, approximately two-thirds are granted patents. l 8 The major trend in patent activity has been the increase in the percentage of foreign devices receiving U.S. patents-from 30 to 40 percent of the total. It appears that U.S. patents offer more protection than those of other countries.
Biotechnology
The newest and by some measures most promising area of health care innovation is in biotechnology. Biotechnology, according to an NIH report, is defined as "any technique that uses living organisms (or parts of organisms) to make or modify products, to improve plants or animals, or to develop microorganisms for specific uses." 19 In health research and development, the recombinant DNA and monoclonal antibody technologies offer promise for innovation by allowing researchers to isolate and manipulate desired parts of genetic material from normal and disease states. In NIH's 1984 report, the authors declare, "Biotechnology has had an impact on the conduct of basic biomedical research comparable perhaps to that of the computer on information processing." One survey predicts that the health care industry will benefit significantly from biotechnology by 1990, earlier than other industries which are implementing biotechnology techniques, such as agriculture, forestry, food ingredients, industrial The total percentage of firms exceeds 100 percent because some companies are applying biotechnology in more than one industrial sector. chemicals, energy, pollution control, mining, and bioelectronics. 20 The basic research in developing biotechnology for biomedical use is funded by the NIH. Estimates for 1985 indicate that the NIH will spend close to $560 million on biotechnology-related research and over $1.26 billion on research supporting the broader science base for biotechnology.
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The private sector, on the other hand, has become heavily involved in developing biotechnology products for commercial application. In 1983, industry invested more than $1 billion to commercialize recombinant DNA, cell fusion, and related technologies. 22 The first major organization to represent biotechnology companies-the Industrial Biotechnology Association-was formed in 1981. Exhibit 7 shows the percentage of U.S. firms pursuing biotechnological applications.
Given the increasing industry involvement in biotechnology R and D and the speed with which innovation is occurring, the growth in biotechnological patent activity is not surprising. Exhibit 8 shows the increase in the number of patents from 1983 to 1984 as well as the slightly increasing proportion of U.S. patents compared to the foreign share. However, the percentage of foreign firms receiving U.S. patents is still significant at 40 percent. Japan leads the foreign firms with 191 US. patents in 1984, or 42.3 percent of the foreign total. West Germany follows with 77 patents, Biotechnology has the capacity to aid health innovation in a number of ways. According to the Office of Technology Assessment's January 1984 report on commercial biotechnology, "Perhaps the most important application of biotechnology is to facilitate further biomedical research. Among the most intriguing areas of research using biotechnology are those pertaining to the nervous system, the immune system, the endocrine system, and cancer." 
Federal Biomedical Research
The federal government has historically played a major role in supporting medical-related R and D, particularly basic research. In 1984, an estimated 52 percent of all public and private health R and D was supported by federal funds Exhibit 9 compares the government level of health R and D investment with that of industry and private nonprofit organizations. Of the total federal research and development budget, health placed second only to defense in 1984. Exhibit 10 shows how the federal government divides its research dollars. When converted to 1982 dollars, the health portion of the 1985 budget request decreases slightly, while defense R and D continues to rise. NIH, at a minimum, should fund 10,500 training positions a year to maintain the nation's capacity to conduct research. 27 Over 80 percent of the NIH 1983 budget was spent on grants and contracts, while the remainder was divided between intramural research, the National Library of Medicine, and administrative functions. 28 The administration's 1986 budget request, which proposes to limit the number of NIH new competing research project grants to 5,000 rather than 6,500 approved by Congress last year, is an attempt at controling this major portion of the NIH budget. The proposal has met with considerable opposition. Until now, Congress has every year appropriated more for the NIH than any administration requested. Exhibit 12 sets forth the administration's 1986 budget request for the NIH.
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